280 related articles for article (PubMed ID: 34386005)
1. Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement.
Liu Y; Wang X; Zhou J; Shi S; Shen T; Chen L; Zhang M; Liao C; Wang C
Front Immunol; 2021; 12():693972. PubMed ID: 34386005
[TBL] [Abstract][Full Text] [Related]
2. Bursal peptide BP-IV as a novel immunoadjuvant enhances the protective efficacy of an epitope peptide vaccine containing T and B cell epitopes of the H9N2 avian influenza virus.
Liu Y; Shen T; Zhou J; Chen L; Shi S; Wang X; Zhang M; Wang C; Liao C
Microb Pathog; 2021 Sep; 158():105095. PubMed ID: 34280501
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Activity of Bursal Pentapeptide-(III-V) in Mice Immunized with the H9N2 Avian Influenza Vaccine.
Zhou J; Zhang C; Liu Z; Liu Y; Cai K; Shen T; Liao C; Wang C
Protein Pept Lett; 2018; 25(8):757-766. PubMed ID: 30081784
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immunoadjuvant activities of four bursal peptides combined with H9N2 avian influenza virus vaccine.
Zhang C; Zhou J; Liu Z; Liu Y; Cai K; Shen T; Liao C; Wang C
J Vet Sci; 2018 Nov; 19(6):817-826. PubMed ID: 30173497
[TBL] [Abstract][Full Text] [Related]
5. Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.
Kim KH; Jung YJ; Lee Y; Park BR; Oh J; Lee YN; Kim MC; Jeeva S; Kang SM
Virology; 2020 Nov; 550():51-60. PubMed ID: 32882637
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.
Dabaghian M; Latify AM; Tebianian M; Nili H; Ranjbar AR; Mirjalili A; Mohammadi M; Banihashemi R; Ebrahimi SM
Vet Microbiol; 2014 Nov; 174(1-2):116-26. PubMed ID: 25293397
[TBL] [Abstract][Full Text] [Related]
7. Improvement influenza HA2 DNA vaccine cellular and humoral immune responses with Mx bio adjuvant.
Soleimani S; Shahsavandi S; Maddadgar O
Biologicals; 2017 Mar; 46():6-10. PubMed ID: 28027847
[TBL] [Abstract][Full Text] [Related]
8. An amphiphilic invertible polymer as a delivery vehicle for a M2e-HA2-HA1 peptide vaccine against an Influenza A virus in pigs.
Singh G; Zholobko O; Pillatzki A; Webb B; Nelson E; Voronov A; Ramamoorthy S
Vaccine; 2019 Jul; 37(31):4291-4301. PubMed ID: 31235376
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Immune Responses to an Inactivated Avian Influenza Virus Vaccine Adjuvanted with Nanoparticles Containing CpG ODN.
Singh SM; Alkie TN; Abdelaziz KT; Hodgins DC; Novy A; Nagy É; Sharif S
Viral Immunol; 2016 Jun; 29(5):269-75. PubMed ID: 27077969
[TBL] [Abstract][Full Text] [Related]
10. Bursopentine as a novel immunoadjuvant enhances both humoral and cell-mediated immune responses to inactivated H9N2 Avian Influenza virus in chickens.
Li D; Xue M; Wang C; Wang J; Chen P
Clin Vaccine Immunol; 2011 Sep; 18(9):1497-502. PubMed ID: 21795462
[TBL] [Abstract][Full Text] [Related]
11. A novel M2e based flu vaccine formulation for dogs.
Leclerc D; Rivest M; Babin C; López-Macias C; Savard P
PLoS One; 2013; 8(10):e77084. PubMed ID: 24098576
[TBL] [Abstract][Full Text] [Related]
12. Bursin-like peptide (BLP) enhances H9N2 influenza vaccine induced humoral and cell mediated immune responses.
Wang C; Li X; Wu T; Li D; Niu M; Wang Y; Zhang C; Cheng X; Chen P
Cell Immunol; 2014; 292(1-2):57-64. PubMed ID: 25282449
[TBL] [Abstract][Full Text] [Related]
13. Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
Astill J; Alkie T; Yitbarek A; Taha-Abdelaziz K; Bavananthasivam J; Nagy É; Petrik JJ; Sharif S
Vaccine; 2018 Jun; 36(27):3908-3916. PubMed ID: 29853199
[TBL] [Abstract][Full Text] [Related]
14. Enhancing immunogenicity and protective efficacy of inactivated avian influenza H9N2vaccine with recombinant chicken IFN-α in chicken.
Gan L; Tian Y; Zhao Y; Shan XQ; Zhou W; Xia BB; Chen J; Wang ML; Zhao J
Vet Microbiol; 2019 Jul; 234():77-82. PubMed ID: 31213275
[TBL] [Abstract][Full Text] [Related]
15. Recombinant influenza H9N2 virus with a substitution of H3 hemagglutinin transmembrane domain showed enhanced immunogenicity in mice and chicken.
Zhang Y; Wei Y; Liu K; Huang M; Li R; Wang Y; Liu Q; Zheng J; Xue C; Cao Y
Sci Rep; 2017 Dec; 7(1):17923. PubMed ID: 29263359
[TBL] [Abstract][Full Text] [Related]
16. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.
Qiu M; Fang F; Chen Y; Wang H; Chen Q; Chang H; Wang F; Wang H; Zhang R; Chen Z
Biochem Biophys Res Commun; 2006 May; 343(4):1124-31. PubMed ID: 16580631
[TBL] [Abstract][Full Text] [Related]
17. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
[TBL] [Abstract][Full Text] [Related]
18. Modification of neutralizing epitopes of hemagglutinin for the development of broadly protective H9N2 vaccine.
Poh ZW; Wang Z; Kumar SR; Yong HY; Prabakaran M
Vaccine; 2020 Feb; 38(6):1286-1290. PubMed ID: 31924429
[TBL] [Abstract][Full Text] [Related]
19. A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
Wodal W; Falkner FG; Kerschbaum A; Gaiswinkler C; Fritz R; Kiermayr S; Portsmouth D; Savidis-Dacho H; Coulibaly S; Piskernik C; Hohenadl C; Howard MK; Kistner O; Barrett PN; Kreil TR
Vaccine; 2012 Jun; 30(31):4625-31. PubMed ID: 22580355
[TBL] [Abstract][Full Text] [Related]
20. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
